Annual Financials for Lipocine Inc.
Fiscal year is January-December. All values USD millions. |
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
Sales/Revenue
|
- | 428,031 | 164,990 | - | 16.14M | |
Sales Growth |
- | - | -61.45% | - | - | |
Cost of Goods Sold (COGS) incl. D&A |
28,370 | - | - | 3,554 | 380 | |
COGS excluding D&A |
- | - | - | - | - | |
Depreciation & Amortization Expense |
28,370 | 18,595 | 15,443 | 3,554 | 380 | |
Depreciation |
28,370 | 18,595 | 15,443 | 3,554 | 380 | |
Amortization of Intangibles |
- | - | - | - | - | |
COGS Growth |
- | - | - | - | -89.31% | |
Gross Income |
(28,370) | - | - | (3,554) | 16.14M | |
Gross Income Growth |
- | - | - | - | 454,249.07% | |
Gross Profit Margin |
- | - | - | - | 100.00% | NA |
|
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
SG&A Expense |
21.19M | 11.74M | 13.05M | 17.99M | 12.99M | |
Research & Development |
11M | 6.46M | 7.45M | 9.74M | 7.67M | |
Other SG&A |
10.19M | 5.27M | 5.6M | 8.25M | - | |
SGA Growth |
- | -44.62% | 11.20% | 37.88% | -27.78% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
- | - | (236,400) | 2.66M | 3.64M | |
EBIT after Unusual Expense |
- | - | (12.66M) | (20.65M) | (498,610) | |
Non Operating Income/Expense |
235,820 | - | - | - | - | |
Non-Operating Interest Income |
- | 459,497 | - | 75,650 | 67,700 | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
- | 793,000 | 343,254 | 386,618 | 203,292 | |
Interest Expense Growth |
- | - | -56.71% | 12.63% | -47.42% | |
Gross Interest Expense |
- | 793,000 | 343,254 | 386,618 | 203,292 | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
(20.98M) | (11.66M) | (13.01M) | (20.96M) | (634,199) | |
Pretax Income Growth |
- | 44.43% | -11.56% | -61.18% | 96.97% | |
Pretax Margin |
- | - | - | - | -3.93% | NA |
Income Tax |
700 | 700 | 200 | 200 | 200 | |
Income Tax - Current Domestic |
700 | 700 | 200 | 200 | 200 | |
Income Tax - Current Foreign |
- | - | - | - | - | |
Income Tax - Deferred Domestic |
- | - | - | - | - | |
Income Tax - Deferred Foreign |
- | - | - | - | - | |
Income Tax Credits |
- | - | - | - | - | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
(20.98M) | (11.66M) | (13.01M) | (20.96M) | (634,399) | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
(20.98M) | (11.66M) | (13.01M) | (20.96M) | (634,399) | |
Net Income Growth |
- | 44.43% | -11.56% | -61.18% | 96.97% | |
Net Margin Growth |
- | - | - | - | -3.93% | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
(20.98M) | (11.66M) | (13.01M) | (20.96M) | (634,399) | |
Preferred Dividends |
- | - | - | - | - | |
Net Income Available to Common |
(20.98M) | (11.66M) | (13.01M) | (20.96M) | (634,399) | |
EPS (Basic) |
(1.05) | (0.55) | (0.50) | (0.38) | (0.01) | |
EPS (Basic) Growth |
- | 47.99% | 7.97% | 25.09% | 98.06% | |
Basic Shares Outstanding |
20.05M | 21.35M | 25.88M | 55.69M | 86.93M | |
EPS (Diluted) |
(1.05) | (0.55) | (0.50) | (0.38) | (0.01) | |
EPS (Diluted) Growth |
- | 47.99% | 7.97% | 25.09% | 98.06% | |
Diluted Shares Outstanding |
20.05M | 21.35M | 25.88M | 55.69M | 86.93M | |
EBITDA |
(21.19M) | (11.31M) | (12.88M) | (17.99M) | 3.15M | |
EBITDA Growth |
- | 46.64% | -13.95% | -39.64% | 117.48% | |
EBITDA Margin |
- | - | - | - | 19.49% | NA |